Oseltamivir-resistant pandemic (H1N1)2009 in Yemen - case report [PDF]
Background During the influenza season of 2007-08, oseltamivir-resistant influenza A (H1N1) viruses emerged in several countries in Europe, North America, and Asia.
Ahmed AK Thabet +7 more
core +4 more sources
Occurrence and characterization of oseltamivir-resistant influenza virus in children between 2007-2008 and 2008-2009 seasons [PDF]
PurposeThere was a global increase in the prevalence of oseltamivir-resistant influenza viruses during the 2007-2008 influenza season. This study was conducted to investigate the occurrence and characteristics of oseltamivir-resistant influenza viruses ...
American Academy of Pediatrics Committee on Infectious Diseases +40 more
core +3 more sources
Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. [PDF]
Oseltamivir is the main antiviral for treatment and prevention of pandemic influenza. The increase in oseltamivir resistance reported recently has therefore sparked a debate on how to use oseltamivir in non pandemic influenza and the risks associated ...
Jerker Fick +6 more
doaj +1 more source
Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. [PDF]
Influenza viruses resistant to antiviral drugs emerge frequently. Not surprisingly, the widespread treatment in many countries of patients infected with 2009 pandemic influenza A (H1N1) viruses with the neuraminidase (NA) inhibitors oseltamivir and ...
Maki Kiso +11 more
doaj +1 more source
The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans. [PDF]
Human carboxylesterase 1 (CES1) is a serine esterase that hydrolyses various exogenous and endogenous compounds including oseltamivir, a prodrug used to treat influenza. A novel CES1 c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease
Jaeseong Oh +7 more
doaj +1 more source
Background: Oseltamivir has been used as adjunctive therapy in the management of patients with COVID-19. However, the evidence about using oseltamivir in critically ill patients with severe COVID-19 remains scarce.
Ohoud Aljuhani +19 more
doaj +1 more source
Oseltamivir is a widely used influenza virus neuraminidase (NA) inhibitor that prevents the release of new virus particles from host cells. However, oseltamivir-resistant strains have emerged, but effective drugs against them have not yet been developed.
Jiaye Tao +18 more
doaj +1 more source
Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis. [PDF]
BACKGROUND:Influenza is a common viral respiratory infection that causes epidemics and pandemics in the human population. Oseltamivir is a neuraminidase inhibitor-a new class of antiviral therapy for influenza.
Kunling Shen +3 more
doaj +1 more source
Background: As a cause of respiratory tract infections in humans, influenza remains with high morbidity and mortality, with associated significant healthcare burden and increased financial burden.
Yingying Peng +16 more
doaj +1 more source
Evaluating the effects of oseltamivir phosphate on platelet counts: a retrospective review
Desialylation of platelets results in platelet clearance by the Ashwell-Morrell Receptors (AMR) found on hepatocytes. Studies suggest that oseltamivir phosphate inhibits human sialidases, enzymes responsible for desialylation, extending the lifespan of ...
Hila Shaim +4 more
doaj +1 more source

